T
Tsukasa Matsubara
Researcher at Toho University
Publications - 58
Citations - 2537
Tsukasa Matsubara is an academic researcher from Toho University. The author has contributed to research in topics: Rheumatoid arthritis & Abatacept. The author has an hindex of 19, co-authored 49 publications receiving 2345 citations.
Papers
More filters
Journal ArticleDOI
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis.
Akari Suzuki,Ryo Yamada,Xiaotian Chang,Shinya Tokuhiro,Tetsuji Sawada,Masakatsu Suzuki,Miyuki Nagasaki,Makiko Nakayama-Hamada,Reimi Kawaida,Mitsuru Ono,Masahiko Ohtsuki,Hidehiko Furukawa,Shinichi Yoshino,Masao Yukioka,Shigeto Tohma,Tsukasa Matsubara,Shigeyuki Wakitani,Ryota Teshima,Yuichi Nishioka,Akihiro Sekine,Aritoshi Iida,Atsushi Takahashi,Tatsuhiko Tsunoda,Yusuke Nakamura,Kazuhiko Yamamoto +24 more
TL;DR: The results imply that the PADI4 haplotype associated with susceptibility to rheumatoid arthritis increases production of citrullinated peptides acting as autoantigens, resulting in heightened risk of developing the disease.
Journal ArticleDOI
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population
Yukinori Okada,Chikashi Terao,Katsunori Ikari,Yuta Kochi,Koichiro Ohmura,Akari Suzuki,Takahisa Kawaguchi,Eli A. Stahl,Eli A. Stahl,Fina A S Kurreeman,Fina A S Kurreeman,Fina A S Kurreeman,Nao Nishida,Hiroko Ohmiya,Keiko Myouzen,Meiko Takahashi,Tetsuji Sawada,Yuichi Nishioka,Masao Yukioka,Tsukasa Matsubara,Shigeyuki Wakitani,Ryota Teshima,Shigeto Tohma,Kiyoshi Takasugi,Kota Shimada,Akira Murasawa,Shigeru Honjo,Keitaro Matsuo,Hideo Tanaka,Kazuo Tajima,Taku Suzuki,Takuji Iwamoto,Yoshiya Kawamura,Hisashi Tanii,Yuji Okazaki,Tsukasa Sasaki,Peter K. Gregersen,Leonid Padyukov,Jane Worthington,Katherine A. Siminovitch,Mark Lathrop,Atsuo Taniguchi,Atsushi Takahashi,Katsushi Tokunaga,Michiaki Kubo,Yusuke Nakamura,Naoyuki Kamatani,Tsuneyo Mimori,Robert M. Plenge,Robert M. Plenge,Hisashi Yamanaka,Shigeki Momohara,Ryo Yamada,Fumihiko Matsuda,Kazuhiko Yamamoto +54 more
TL;DR: This study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10−8, including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.
Journal ArticleDOI
Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
Atsushi Ogata,Kazuhide Tanimura,Toyohiko Sugimoto,Hiroshi Inoue,Yukitomo Urata,Tsukasa Matsubara,Masakazu Kondo,Yukitaka Ueki,Mitsuhiro Iwahashi,Shigeto Tohma,Shuji Ohta,Yukihiko Saeki,Toshio Tanaka +12 more
TL;DR: To evaluate the efficacious noninferiority of subcutaneous tocilizumab injection to intravenous TCZ infusion monotherapy in Japanese patients with rheumatoid arthritis with an inadequate response to synthetic and/or biologic disease‐modifying antirheumatic drugs (DMARDs).
Journal ArticleDOI
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
Norihiro Nishimoto,Norihiro Nishimoto,Koichi Amano,Yasuhiko Hirabayashi,Takahiko Horiuchi,Tomonori Ishii,Mitsuhiro Iwahashi,Masahiro Iwamoto,Hitoshi Kohsaka,Masakazu Kondo,Tsukasa Matsubara,Toshihide Mimura,Hisaaki Miyahara,Shuji Ohta,Yukihiko Saeki,Kazuyoshi Saito,Hajime Sano,Kiyoshi Takasugi,Tsutomu Takeuchi,Shigeto Tohma,Tomomi Tsuru,Yukitaka Ueki,Jiro Yamana,Jun Hashimoto,Takaji Matsutani,Miho Murakami,Miho Murakami,Nobuhiro Takagi +27 more
TL;DR: TCZ monotherapy may induce biologics-free remission or LDA without concomitant use of synthetic DMARDs and Serum levels of IL-6 and MMP-3 are useful markers for identifying patients who could discontinue TCZ without acute disease flare.
Journal ArticleDOI
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
Tsutomu Takeuchi,Hisashi Yamanaka,Naoki Ishiguro,Nobuyuki Miyasaka,Masaya Mukai,Tsukasa Matsubara,Shoji Uchida,Hideto Akama,Hartmut Kupper,Vipin Arora,Yoshiya Tanaka +10 more
TL;DR: Adalimumab in combination with low-dose MTX was well tolerated and efficacious in suppressing radiographic progression and improving clinical outcomes in Japanese patients with early RA and high disease activity.